-+ 0.00%
-+ 0.00%
-+ 0.00%
Corsera Health starts Phase 1 trial of dual-targeting cardiovascular disease prevention therapy
Share
Listen to the news
Corsera Health starts Phase 1 trial of dual-targeting cardiovascular disease prevention therapy
  • Corsera Health initiated a Phase 1 cardiovascular prevention trial of COR-2003 alone and in combination with COR-1004 in Australia and New Zealand.
  • The combination targets LDL cholesterol and blood pressure, with development aimed at a once-yearly subcutaneous injection.
  • COR-1004 achieved initial clinical proof of concept in a separate ongoing Phase 1 trial.
  • Initial COR-2003 proof-of-concept data are expected in early 2027, followed by combination data in mid-2027.
  • A Phase 2 trial of the dual-targeting medicine is planned by the end of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending